Formulation and evaluation of cetuximab functionalized phospholipid modified nanocrystals of paclitaxel for non-small cell lung cancer therapy

Abstract Present work aims to prepare Soluplus stabilized, phospholipid-modified, and cetuximab-conjugated paclitaxel nanocrystals (NCs) as stable nanocarriers for targeted drug delivery. The NCs, prepared using concurrent antisolvent precipitation cum cold crystallization method followed by probe s...

Full description

Saved in:
Bibliographic Details
Main Authors: Manish Kumar, Pooja Goswami, Abhishek Jha, Manjit Manjit, Amol Parasram Satpute, Biplob Koch, Brahmeshwar Mishra
Format: Article
Language:English
Published: Nature Portfolio 2024-11-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-024-80283-8
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846147877128110080
author Manish Kumar
Pooja Goswami
Abhishek Jha
Manjit Manjit
Amol Parasram Satpute
Biplob Koch
Brahmeshwar Mishra
author_facet Manish Kumar
Pooja Goswami
Abhishek Jha
Manjit Manjit
Amol Parasram Satpute
Biplob Koch
Brahmeshwar Mishra
author_sort Manish Kumar
collection DOAJ
description Abstract Present work aims to prepare Soluplus stabilized, phospholipid-modified, and cetuximab-conjugated paclitaxel nanocrystals (NCs) as stable nanocarriers for targeted drug delivery. The NCs, prepared using concurrent antisolvent precipitation cum cold crystallization method followed by probe sonication, were found to be monodispersed particles with sub-200 nm size. The microscopic analysis uncovered rod and spherical anisotropy for Soluplus stabilized (PTX-NCs) and phospholipid modified (Lipid/PTX-NCs) nanocrystals, respectively. The formation of amorphous PTX-NCs and subsequent coating with phospholipid was confirmed by solid-state characterization using differential scanning calorimetry (DSC), X-ray diffraction (XRD), and Fourier transform Infrared Spectroscopy (FTIR). X-ray Photoelectron Spectroscopic (XPS) analysis, indicated successful conjugation of cetuximab on NCs surface. Lipid coating rendered a sustained drug release behaviour to NCs at physiological pH. In vitro cell line studies confirmed the improved cellular internalization and better apoptosis induction capability of NCs, consequently resulting in enhanced efficacy of PTX against A549 cancer cells. Moreover, in Benzo[a] pyrene-induced lung cancer model, Cmab/Lipid/PTX-NCs showed significant improvement in tumor inhibition potential in comparison to pure PTX. The prepared Cmab/Lipid/PTX-NCs also exhibited improved pharmacokinetics performance, avoided off-target distribution, and showed a reduction in systemic toxicity. The findings of this study indicate the promising potential of the prepared cetuximab-functionalized phospholipid-coated paclitaxel nanocrystals in lung cancer therapy.
format Article
id doaj-art-4642486f7cec4f29b764d02f79194815
institution Kabale University
issn 2045-2322
language English
publishDate 2024-11-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-4642486f7cec4f29b764d02f791948152024-12-01T12:20:04ZengNature PortfolioScientific Reports2045-23222024-11-0114111810.1038/s41598-024-80283-8Formulation and evaluation of cetuximab functionalized phospholipid modified nanocrystals of paclitaxel for non-small cell lung cancer therapyManish Kumar0Pooja Goswami1Abhishek Jha2Manjit Manjit3Amol Parasram Satpute4Biplob Koch5Brahmeshwar Mishra6Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU)Genotoxicology and Cancer Biology Laboratory, Department of Zoology, Institute of Science, Banaras Hindu UniversityDepartment of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU)Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU)Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU)Genotoxicology and Cancer Biology Laboratory, Department of Zoology, Institute of Science, Banaras Hindu UniversityDepartment of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU)Abstract Present work aims to prepare Soluplus stabilized, phospholipid-modified, and cetuximab-conjugated paclitaxel nanocrystals (NCs) as stable nanocarriers for targeted drug delivery. The NCs, prepared using concurrent antisolvent precipitation cum cold crystallization method followed by probe sonication, were found to be monodispersed particles with sub-200 nm size. The microscopic analysis uncovered rod and spherical anisotropy for Soluplus stabilized (PTX-NCs) and phospholipid modified (Lipid/PTX-NCs) nanocrystals, respectively. The formation of amorphous PTX-NCs and subsequent coating with phospholipid was confirmed by solid-state characterization using differential scanning calorimetry (DSC), X-ray diffraction (XRD), and Fourier transform Infrared Spectroscopy (FTIR). X-ray Photoelectron Spectroscopic (XPS) analysis, indicated successful conjugation of cetuximab on NCs surface. Lipid coating rendered a sustained drug release behaviour to NCs at physiological pH. In vitro cell line studies confirmed the improved cellular internalization and better apoptosis induction capability of NCs, consequently resulting in enhanced efficacy of PTX against A549 cancer cells. Moreover, in Benzo[a] pyrene-induced lung cancer model, Cmab/Lipid/PTX-NCs showed significant improvement in tumor inhibition potential in comparison to pure PTX. The prepared Cmab/Lipid/PTX-NCs also exhibited improved pharmacokinetics performance, avoided off-target distribution, and showed a reduction in systemic toxicity. The findings of this study indicate the promising potential of the prepared cetuximab-functionalized phospholipid-coated paclitaxel nanocrystals in lung cancer therapy.https://doi.org/10.1038/s41598-024-80283-8NanocrystalsPaclitaxelCetuximabLung cancer
spellingShingle Manish Kumar
Pooja Goswami
Abhishek Jha
Manjit Manjit
Amol Parasram Satpute
Biplob Koch
Brahmeshwar Mishra
Formulation and evaluation of cetuximab functionalized phospholipid modified nanocrystals of paclitaxel for non-small cell lung cancer therapy
Scientific Reports
Nanocrystals
Paclitaxel
Cetuximab
Lung cancer
title Formulation and evaluation of cetuximab functionalized phospholipid modified nanocrystals of paclitaxel for non-small cell lung cancer therapy
title_full Formulation and evaluation of cetuximab functionalized phospholipid modified nanocrystals of paclitaxel for non-small cell lung cancer therapy
title_fullStr Formulation and evaluation of cetuximab functionalized phospholipid modified nanocrystals of paclitaxel for non-small cell lung cancer therapy
title_full_unstemmed Formulation and evaluation of cetuximab functionalized phospholipid modified nanocrystals of paclitaxel for non-small cell lung cancer therapy
title_short Formulation and evaluation of cetuximab functionalized phospholipid modified nanocrystals of paclitaxel for non-small cell lung cancer therapy
title_sort formulation and evaluation of cetuximab functionalized phospholipid modified nanocrystals of paclitaxel for non small cell lung cancer therapy
topic Nanocrystals
Paclitaxel
Cetuximab
Lung cancer
url https://doi.org/10.1038/s41598-024-80283-8
work_keys_str_mv AT manishkumar formulationandevaluationofcetuximabfunctionalizedphospholipidmodifiednanocrystalsofpaclitaxelfornonsmallcelllungcancertherapy
AT poojagoswami formulationandevaluationofcetuximabfunctionalizedphospholipidmodifiednanocrystalsofpaclitaxelfornonsmallcelllungcancertherapy
AT abhishekjha formulationandevaluationofcetuximabfunctionalizedphospholipidmodifiednanocrystalsofpaclitaxelfornonsmallcelllungcancertherapy
AT manjitmanjit formulationandevaluationofcetuximabfunctionalizedphospholipidmodifiednanocrystalsofpaclitaxelfornonsmallcelllungcancertherapy
AT amolparasramsatpute formulationandevaluationofcetuximabfunctionalizedphospholipidmodifiednanocrystalsofpaclitaxelfornonsmallcelllungcancertherapy
AT biplobkoch formulationandevaluationofcetuximabfunctionalizedphospholipidmodifiednanocrystalsofpaclitaxelfornonsmallcelllungcancertherapy
AT brahmeshwarmishra formulationandevaluationofcetuximabfunctionalizedphospholipidmodifiednanocrystalsofpaclitaxelfornonsmallcelllungcancertherapy